Department of Biomedical Sciences, University of Copenhagen, Copenhagen N, Denmark.
Department of Health Science and Technology, University of Aalborg, Aalborg, Denmark.
Exp Physiol. 2020 May;105(5):819-830. doi: 10.1113/EP088165. Epub 2020 Apr 20.
What is the central question of this study? Can antiarrhythmic drug effects on repolarization, conduction time and excitation wavelength in premature beats be determined by prior cardiac activation frequency? What is the main finding and its importance? In premature beats induced after a series of cardiac activations at a slow rate, antiarrhythmics prolong repolarization but evoke little or no conduction delay, thus increasing the excitation wavelength, which indicates an antiarrhythmic effect. Fast prior activation rate attenuates prolongation of repolarization, while amplifying the conduction delay induced by drugs, which translates into the reduced excitation wavelength, indicating proarrhythmia. These findings suggest that a sudden increase in heart rate can shape adverse pharmacological profiles in patients with ventricular ectopy.
Antiarrhythmic drugs used to treat atrial fibrillation can occasionally induce ventricular tachyarrhythmia, which is typically precipitated by a premature ectopic beat through a mechanism related, in part, to the shortening of the excitation wavelength (EW). The arrhythmia is likely to occur when a drug induces a reduction, rather than an increase, in the EW of ectopic beats. In this study, I examined whether the arrhythmic drug profile is shaped by the increased cardiac activation rate before ectopic excitation. Ventricular monophasic action potential durations, conduction times and EW values were assessed during programmed stimulations applied at long (S -S [basic drive cycle length] = 550 ms) and short (S -S = 200 ms) cycle lengths in perfused guinea-pig hearts. The premature activations were induced with extrastimulus application immediately upon termination of the refractory period. With dofetilide, a class III antiarrhythmic agent, a prolongation in action potential duration and the resulting increase in the EW obtained at S -S = 550 ms were significantly attenuated at S -S = 200 ms, in both the regular (S ) and the premature (S ) beats. With class I antiarrhythmic agents (quinidine, procainamide and flecainide), fast S -S pacing was found to attenuate the drug-induced increase in action potential duration, while amplifying drug-induced conduction slowing, in both S and S beats. As a result, although the EW was increased (quinidine and procainamide) or not changed (flecainide) at the long S -S intervals, it was invariably reduced by these agents at the short S -S intervals. These findings indicate that the increased heart rate before ectopic activation shapes the arrhythmic profiles by facilitating drug-induced EW reduction.
这项研究的核心问题是什么?先前的心脏激活频率是否可以决定抗心律失常药物对早搏复极、传导时间和兴奋波长的影响?主要发现及其重要性是什么?在慢心率诱导的早搏后,抗心律失常药物会延长复极,但引起的传导延迟很小或没有,从而增加兴奋波长,表明有抗心律失常作用。快速的先前激活率会减弱复极的延长,同时放大药物引起的传导延迟,从而转化为减少的兴奋波长,表明致心律失常。这些发现表明,心率的突然增加可能会改变室性异位患者的不良药物谱。
用于治疗心房颤动的抗心律失常药物偶尔会引发室性心动过速,这通常是由早搏通过一种部分与缩短兴奋波长(EW)相关的机制引起的。当药物引起 EW 减少而不是增加时,心律失常很可能发生。在这项研究中,我研究了异位兴奋前增加的心脏激活率是否会影响心律失常药物谱。在灌注豚鼠心脏中,通过程控刺激在长(S -S [基本驱动周期长度] = 550 ms)和短(S -S = 200 ms)周期长度下评估心室单相动作电位时程、传导时间和 EW 值。早搏是在不应期结束时立即施加的额外刺激下诱发的。对于类 III 抗心律失常药物多非利特,在 S -S = 200 ms 时,与 S -S = 550 ms 时相比,动作电位时程的延长和由此产生的 EW 增加显著减弱,无论是在规则(S )还是在早搏(S )中。对于 I 类抗心律失常药物(奎尼丁、普鲁卡因胺和氟卡尼),快速 S -S 起搏被发现会减弱药物引起的动作电位时程延长,同时放大药物引起的传导减慢,无论是在 S 和 S 中。因此,尽管在长 S -S 间隔时,奎尼丁和普鲁卡因胺增加了 EW,氟卡尼没有改变 EW,但这些药物在短 S -S 间隔时总是降低了 EW。这些发现表明,异位激活前的心率增加通过促进药物诱导的 EW 减少来塑造心律失常谱。